{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'TYPE OF SUBJECT AND DIAGNOSIS INCLUDING DISEASE SEVERITY', '2. Outpatient with a diagnosis of COPD in accordance with the definition of the', 'American Thoracic Society/European Respiratory Society (ATS/ERS) [Celli, 2004].', '3.', 'FEV1 Persistent airflow limitations as indicated by: A pre and post-', 'albuterol/salbutamol FEV1/FVC ratio of <0.70 and a post-albuterol/salbutamo FEV1', 'of >30% to 80% predicted normal values at Screening Visit 1. Predicted values', 'will be based upon the ERS Global Lung Function Initiative [Quanjer, 2012].', '4.', 'CAT score: A CAT score of >10 at Screening Visit 1', 'Smoking History', '5. Current or former cigarette smokers with a history of cigarette smoking of 10', 'pack-years [number of pack years = (number of cigarettes per day / 20) x number of', 'years smoked (e.g. 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20', 'years both equal 10 pack-years)] Former smokers are defined as those who have', 'stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use cannot', 'be used to calculate pack-year history.', 'SEX', '6.', 'Male and female subjects are eligible to participate in the study', 'A female subject is eligible to participate if she is not pregnant (as confirmed by a', 'negative urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one', 'of the following conditions applies:', 'a.', 'Non-reproductive potential defined as:', 'Pre-menopausal females with one of the following:', 'Documented tubal ligation', 'Documented hysteroscopic tubal occlusion procedure with follow-up', 'confirmation of bilateral tubal occlusion', 'Hysterectomy', 'Documented Bilateral Oophorectomy', 'Postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases', 'a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels', 'consistent with menopause must be tested. Females on hormone replacement therapy', '(HRT) and whose menopausal status is in doubt will be required to use one of the highly', 'effective contraception methods if they wish to continue their HRT during the study.', 'Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status', 'prior to study enrolment.', 'b. Reproductive potential and agrees to follow one of the options listed in the Modified', 'List of Highly Effective Methods for Avoiding Pregnancy in Females of', '26']['2016N277425_01', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Reproductive Potential (FRP) (Appendix 7) from 30 days prior to the first dose of', 'study medication and until [at least five terminal half-lives OR until any continuing', 'pharmacologic effect has ended, whichever is longer] after the last dose of study', 'medication and completion of the follow-up visit.', 'The investigator is responsible for ensuring that subjects understand how to properly use', 'these methods of contraception.', 'INFORMED CONSENT', '7. Capable of giving signed informed consent prior to study participation, which', 'includes compliance with the requirements and restrictions listed in the consent form', 'and in this protocol.', '5.2.', 'Exclusion Criteria', 'A subject will not be eligible for inclusion in this study if any of the following criteria', 'apply:', 'CONCURRENT CONDITIONS/MEDICAL HISTORY (INCLUDES LIVER', 'FUNCTION', '1.', 'Asthma: A current diagnosis of asthma. (Subjects with a prior history of asthma', 'are eligible if they have a current diagnosis of COPD, which is the primary cause of', 'their respiratory symptoms).', '2.', 'Alpha-antitrypsin deficiency: Subjects with known ul-antitrypsin deficiency as', 'the underlying cause of COPD', '3.', 'Other respiratory disorders: Subjects with active tuberculosis are excluded.', 'Subjects with other respiratory disorders (e.g. clinically significant:', 'bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial', 'lung diseases) are excluded if these conditions are the primary cause of their', 'respiratory symptoms.', '4.', 'Unstable liver disease: Current active liver or biliary disease (with the exception', \"of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic\", 'liver disease per investigator assessment).', 'Stable chronic liver disease should generally be defined by the absence of ascites,', 'encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric', 'varices, or persistent jaundice, or cirrhosis.', 'Chronic stable hepatitis B and C (e.g., presence of hepatitis B surface antigen', '(HBsAg) or positive hepatitis C antibody test result or within 3 months prior to', 'first dose of study treatment) are acceptable if subject otherwise meets entry', 'criteria', '5.', 'Unstable or life threatening cardiac disease: Investigational Product should be', 'used with caution in subjects with severe cardiovascular disease. In the opinion', 'of the investigator, use should only be considered if the benefit is likely to', '27']\n\n###\n\n", "completion": "END"}